翻訳と辞書 |
CERC-501
CERC-501 (formerly known as LY-2456302) is a selective, short-acting antagonist of the κ-opioid receptor (Ki = 0.81 nM vs. 24.0 nM and 155 nM for the μ- and δ-opioid receptors, respectively). The molecule is being developed as a psychiatric drug by Cerecor Inc. of Baltimore. It was originally developed by Eli Lily as an augmentation to antidepressant therapy for treatment-resistant depression, under the name LY-2456302, and was under phase II clinical trials in the United States. In animal models of depression, CERC-501 has been found to have potent synergistic efficacy in combination with other antidepressants such as citalopram and imipramine.〔 In February 2015, Cerecor Inc. announced that they have acquired the rights to develop and commercialize the molecule. ==See also==
* ALKS-5461 * PF-4455242 * JDTic * Rapastinel * NSI-189
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「CERC-501」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|